FDA OKs Neurocrine’s opicapone for Parkinson’s

The FDA approves Neurocrine Biosciences’ (NASDAQ:NBIX) Ongentys (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “OFF” episodes (times when the medication stops working and symptoms recur).

Market launch will commence later this year.

Shares up 5% premarket on light volume.

https://seekingalpha.com/news/3564600-fda-oks-neurocrines-opicapone-for-parkinsons-shares-up-5-premarket